Release date: 2026-01-05 14:09:26 Recommended: 23
It is indicated for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) classified as New York Heart Association (NYHA) Class Ⅱ-Ⅲ, to improve their functiona